Newsroom
News and developments from Affinia Therapeutics
For media inquiries: media@affiniatx.com.
- All
- Press Releases
- Publications
- Presentations
Press Release - April 22, 2024
Affinia Therapeutics to Present Data on Novel Cardiotropic and BBB-Penetrant AAV Capsids and Preclinical Efficacy and Safety in Genetic Cardiomyopathies and Sporadic ALS at the American Society of Gene & Cell Therapy 2024 Annual Meeting
Read MorePress Release - Oct 24, 2023
Affinia Therapeutics to Present Preclinical Data on Novel AAV Capsids at the 30th European Society of Gene and Cell Therapy 2023 Annual Congress
Read MoreASGCT 2023 Oral Presentation - May 18, 2023
Structure-activity relationships guided engineering of AAV capsids with optimized skeletal muscle, cardiac muscle, and CNS tropism.
Read MoreASGCT 2023 Poster Presentation - May 18, 2023
Improvement of Yield and Critical Quality Attributes Through Process Development of a Novel Adeno-Associated Viral Vector Capsid (Anc80L65)
Read MoreASGCT 2023 Poster Presentation - May 17, 2023
Limitations of Marmosets as an Animal Model for AAV Mediated Liver Gene Transfer.
Read MorePress Release - May 18, 2023
Affinia Therapeutics Presents New Preclinical Data on Novel AAV Capsids for Skeletal Muscle, Cardiac Muscle, and CNS at the American Society of Gene & Cell Therapy 26TH Annual Meeting
Read MorePress Release - May 3, 2023
Affinia Therapeutics to Present New Data at the American Society of Gene and Cell Therapy Annual Meeting
Read MorePresentation - May 16, 2022
Pretreatment with IVIG reduces peripheral transduction of AAV9 delivered to the CNS
Read MorePress Release – May 16, 2022
Affinia Therapeutics Presents New Data at American Society of Gene and Cell Therapy Annual Meeting
Read MorePress Release – March 8, 2022
Affinia Therapeutics Strengthens Leadership Team with Appointment of Diana M. Brainard, M.D., to the Board of Directors
Read MorePress Release – December 14, 2021
Affinia Therapeutics Appoints Thomas Leggett as Chief Financial Officer
Read MorePress Release – October 6, 2021
Affinia Therapeutics Appoints Carole Faig to Board of Directors
Read MorePress Release – September 8, 2021
Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment of Neurologic and Neuro-oncologic Diseases supported by Multi-Year Manufacturing Agreement with Lonza Group
Read MorePress Release – July 20, 2021
Affinia Therapeutics Announces Collaboration with the Institute of Molecular and Clinical Ophthalmology Basel (IOB) To Rationally Design Novel CNS Promoters for Gene Therapy
Read MorePresentation – May 13, 2021
AAVX Resin Binding Site Identification Via Library Screening Analysis on Novel AAV Vectors
Read MorePresentation – May 11, 2021
AAVmod2, an AAV Capsid Engineered to Independently Detarget the Liver and Enhance Gene Delivery to Skeletal Muscle
Read MorePresentation – May 11, 2021
CSF delivery of Anc80L65 in the non-human primate brain results in widespread gene transfer throughout the central nervous system compared to AAV9
Read MorePress Release – May 13, 2021
Affinia Therapeutics Presents New Data and Updates on AAV Platform at American Society of Gene and Cell Therapy Annual Meeting
Read MorePress Release – April 27, 2021
Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting
Read MorePress Release – February 17, 2021
Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic
Read MorePress Release – June 8, 2020
Affinia Therapeutics Announces Appointment of Elliott Sigal, M.D., Ph.D. to the Company’s Board of Directors
Read MorePress Release – April 27 2020
Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies
Read MorePress Release – March 31, 2020
Affinia Therapeutics Raises $60M in Series A Financing to Advance Rational Design AAV Platform and Transformative Gene Therapies
Read MorePublication – Jul 8, 2019
Targeting neuronal and glial cell types with synthetic promoter AAVs in mice, non-human primates and humans
Read MorePublication – Jul 23, 2018
Efficient gene transfer to the central nervous system by single-stranded Anc80L65
Read MorePublication – Aug 11, 2015
In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector
Read MoreYou are now leaving www.affiniatx.com
The website you are linking to is neither owned nor controlled by Affinia Therapeutics. Affinia Therapeutics is not responsible for the content or services of this site.
Continue Return to Affinia website